This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Measure of benefits used in the economic analysis
The two interventions were equally accurate, thus a cost-minimisation analysis appears to have been performed.
Direct costs
The perspective of the hospital appears to have been chosen. The main category of costs was that associated with hospital stay, which was estimated on the basis of changes in turnaround time when using either the in-hospital or the external laboratory. In addition, the cost of developing and performing the test was also considered in a separate analysis. The unit cost of a hospital day was presented separately from the quantities of resources used. Different cost calculations were made. In the period before the use of the in-hospital laboratory (pre-implementation period), the authors contacted all attending physicians in person 2 to 3 days after each PCR test was ordered and before the report of a result, in order to estimate whether the patient would have been discharged if the test results were known. In the post-implementation period (after the introduction of the in-hospital laboratory service), three types of analysis were performed. In the first analysis, all paediatric patients undergoing PCR were considered and one of the authors reviewed their hospital charts in order to estimate the hospital days saved (if any) as a result of the more rapid availability of the result. Adult cases were based on the experience of the attending physicians. Since this evaluation was in part subjective, a second analysis was performed by looking at the actual LOS in days for all patients who had the test performed. Finally, an analysis of LOS in matched pairs was carried out.
Discounting was not relevant as the costs per patient were incurred within a short time. The price year was 2002.
Statistical analysis of costs
The cost-differences were analysed using the chi-squared test. 
Indirect Costs
The indirect costs were not considered.
Currency
US dollars ($).
Sensitivity analysis
Sensitivity analyses were not carried out.
Estimated benefits used in the economic analysis
See the ,Effectiveness Results-section.
Cost results
In the pre-implementation period, attending physicians stated that 4 (of a total of 13) infants would have been discharged at the time they were told the HSV CSF PCR was (hypothetically) negative. In comparison with the time the patient was actually discharged, this would have resulted in a savings of 9 full days (2.25 days per patient) at a direct variable cost of $450 per day (approximately $4,050 throughout a 4-month period, or approximately $12,150 on an annual basis).
The turnaround time was an average of 5.2 (+/-7.2) days (median 4.1; 95% confidence interval, CI: 4.5 to 5.9) before in-house testing and 1.5 (+/-1.0) days (95% CI: 1.3 to 1.7) when performed in-house.
The results of the analysis in the post-implementation period were as follows. Of 32 infants, 5 were thought to have been discharged an average of 2.1 (+/-0.55) (95% CI: 1.4 to 2.8) days per patient sooner than if the PCR test had been sent to the reference laboratory (10.5 total hospital days). Of 23 children aged 30 days to 3 years, 4 were thought to have been discharged an average of 2.9 (+/-0.75) (95% CI: 1.7 to 4.1) days sooner (11.5 days total). Two older children and one adult were judged to have been discharged 2.5, 2.5 and 2 days sooner, respectively. In total, 29 hospital days were estimated to have been saved throughout a 6.3-month period. This corresponds to 55.2 days saved over 1 year, or approximately $27,011 (assuming a direct variable hospital cost of $450 per day for low-intensity neonatal intensive care unit, $502 per day for paediatrics, and $609 per day for adults).
The second analysis of the actual observed LOS showed that a total of 42.1 days were saved throughout the first 7 months of implementation. This projected to an annualised total of 70.2 days. Using the above cost per day estimates, the 70.2-day total shorter LOS would result in annual direct variable cost-savings of approximately $31,590. When these results were broken down by age group, they showed that the shorter LOS was statistically significant only for newborns. Thus, the observed cost-savings were similar to those assessed using the authors' estimates of reduced LOS.
When the lower cost of the in-house test in comparison with the reference laboratory cost was included, an additional annual savings of approximately $11,000 was achieved. Thus, the total saving amounted to $42,590 in the first year, which was greater than the cost of the instrument ($29,000) plus the estimated $8,000 in test development costs (mostly technologists-time).
